Predicting Outcomes in Posttransplant Diabetes Mellitus Via microRNA
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Diabetes Mellitus, Kidney Transplant. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Slovakia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The study aims to improve the prediction and early detection of post-transplant diabetes mellitus (PTDM) in kidney transplant recipients. The investigators are investigating whether specific microRNA profiles measured 3 months after transplantation can reliably predict the development of PTDM within the following one to two years. Additionally, the investigators are evaluating how traditional risk factors-such as age, immunosuppressive therapy, obesity, and infections like CMV-interact with these microRNA markers. The ultimate goal of this research is to identify early indicators of blood sugar issues, enabling timely interventions to improve health outcomes and personalize patient care after kidney transplantation.
Primary outcome measures
- To identify a panel of microRNAs at 3 months post-kidney transplant that are significantly associated with the development of PTDM within a defined follow-up period (e.g., 1 year, 2 years). [Time frame: From enrollment to the end - 12 months]
Eligibility criteria
Inclusion criteria
- Adult patients undergoing kidney transplantation.
- Absence of pre-existing type 1 or type 2 diabetes mellitus.
- Willingness to provide informed consent and comply with study procedures.
Exclusion criteria
- Pre-existing type 1 or type 2 diabetes mellitus.
- Previous organ transplantation.
- Severe comorbidities that could confound the assessment of PTDM (e.g., pancreatic disease).
- Inability to provide informed consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Slovakia · 2 centers
- Transplant-nephorlogy department — Martin
- University hospital Martin — Martin
Identifiers
NCT: NCT07055984 · University hospital Martin